TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY
4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY
4.2.3 GOVERNMENT INITIATIVES FOR GHD
4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS
4.3 RESTRAINTS
4.3.1 HIGH COST OF GHD TREATMENT
4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT
4.4 OPPORTUNITIES
4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS
4.5 CLINICAL TRIALS ANALYSIS
4.6 MEGATRENDS
4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS
4.6.3 PRODUCTS UNDER DEVELOPMENT
4.7 MACROECONOMIC INDICATORS
4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES
4.9 LONG ACTING GROWTH HORMONES (LAGH)
4.9.1 OVERVIEW
4.9.2 DEVELOPMENT
4.9.3 UPCOMING PRODUCTS
4.9.4 TRENDS
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 RESEARCH AND DEVELOPMENT
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING AND SALES
5.1.5 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 RIVALRY
5.3 IMPACT OF COVID-19
5.3.1 OVERVIEW
5.3.2 IMPACT ON SUPPLY CHAIN
5.3.3 IMPACT ON PRODUCTION
5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2022)
6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND
6.1 OVERVIEW
6.2 NORDITROPIN
6.3 GENOTROPIN
6.4 HUMATROPE
6.5 SAIZEN
6.6 OMNITROPE
7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY
7.3 IDIOPATHIC SHORT STATURE
7.4 SMALL FOR GESTATIONAL AGE
7.5 TURNER SYNDROME
7.6 ADULT GROWTH HORMONE DEFICIENCY
7.7 PRADER-WILLI SYNDROME
8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 SUBCUTANEOUS
8.3 INTRAMUSCULAR
8.4 INTRAVENOUS
9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 RETAIL PHARMACIES
9.4 CLINICS
9.5 E-COMMERCE WEBSITES
10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST AND AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2019)
11.3 COMPETITIVE BENCHMARKING
11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 EXPANSION
11.6.2 PRODUCT APPROVAL/FDA APPROVAL
12 COMPANY PROFILES
12.1 MERCK KGAA
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 NOVO NORDISK A/S
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 ELI LILY AND COMPANY
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 F. HOFFMAN LA ROCHE LTD
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 PFIZER, INC.
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 NOVARTIS AG
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 IPSEN PHARMA
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 FERRING PHARMACEUTICALS
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 ANKEBIO CO., LTD
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 CLINICAL TRIALS OVERVIEW
TABLE 4 TREATMENT WITH GROWTH HORMONE AND TERMS OF REIMBURSEMENT IN EUROPEAN COUNTRIES
TABLE 5 COUNTRIES OVERVIEW
TABLE 6 SUMMARY OF LAGH PREPARATION BASED ON CLASS
TABLE 7 WORLDWIDE EPIDEMIOLOGY DATA
TABLE 8 US: EPIDEMIOLOGY DATA
TABLE 9 UK: EPIDEMIOLOGY DATA
TABLE 10 ITALY: EPIDEMIOLOGY DATA
TABLE 11 GERMANY: EPIDEMIOLOGY DATA
TABLE 12 SPAIN: EPIDEMIOLOGY DATA
TABLE 13 FRANCE: EPIDEMIOLOGY DATA
TABLE 14 JAPAN: EPIDEMIOLOGY DATA
TABLE 15 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 16 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR NORDITROPIN, BY REGION, 2022-2032 (USD MILLION)
TABLE 17 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR GENOTROPIN, BY REGION, 2019-2032 (USD MILLION)
TABLE 18 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HUMATROPE, BY REGION, 2019-2032 (USD MILLION)
TABLE 19 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SAIZEN, BY REGION, 2019-2032 (USD MILLION)
TABLE 20 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR OMNITROPE, BY REGION, 2019-2032 (USD MILLION)
TABLE 21 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 22 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PAEDIATRIC GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2032 (USD MILLION)
TABLE 23 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR IDIOPATHIC SHORT STATURE, BY REGION, 2019-2032 (USD MILLION)
TABLE 24 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SMALL FOR GESTATIONAL AGE, BY REGION, 2019-2032 (USD MILLION)
TABLE 25 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR TURNER SYNDROME, BY REGION, 2019-2032 (USD MILLION)
TABLE 26 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR ADULT GROWTH HORMONE DEFICIENCY, BY REGION, 2019-2032 (USD MILLION)
TABLE 27 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR PRADER-WILLI SYNDROME, BY REGION, 2019-2032 (USD MILLION)
TABLE 28 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 29 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2032 (USD MILLION)
TABLE 30 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAMUSCULAR, BY REGION, 2019-2032 (USD MILLION)
TABLE 31 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR INTRAVENOUS, BY REGION, 2019-2032 (USD MILLION)
TABLE 32 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2019-2032 (USD MILLION)
TABLE 34 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR RETAIL PHARMACIES, BY REGION, 2019-2032 (USD MILLION)
TABLE 35 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR CLINICS, BY REGION, 2019-2032 (USD MILLION)
TABLE 36 GLOBAL GROWTH HORMONE DEFICIENCY MARKET FOR E-COMMERCE WEBSITES, BY REGION, 2019-2032 (USD MILLION)
TABLE 37 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 38 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 39 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 40 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 41 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 42 AMERICAS: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 43 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 44 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 45 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 46 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 47 NORTH AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 48 US: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 49 US: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 50 US: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 51 US: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 52 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 53 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 54 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 55 CANADA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 56 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 57 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 58 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 59 LATIN AMERICA: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 60 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 61 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 62 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 63 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 64 EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 65 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 66 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 67 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2022-2032 (USD MILLION)
TABLE 68 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 69 WESTERN EUROPE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 70 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 71 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 72 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 73 GERMANY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 74 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 75 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 76 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 77 FRANCE: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 78 UK: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 79 UK: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 80 UK: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
TABLE 81 UK: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 82 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 83 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
TABLE 84 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD MILLION)
TABLE 85 ITALY: GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 86 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY BRAND, 2019-2032 (USD MILLION)
TABLE 87 SPAIN: GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
